The General Manager EMEA of Wafergen Biosystems discusses the revolutionary nature of the company’s technologies, how they are at the new frontier of genomic research, why Wafergen set up its EMEA office in Luxembourg, growth hotspots in the EMEA region, and the recent merger with Japanese group Takara Bio.
To begin, could you please introduce Wafergen and its proprietary technologies?
"There are several sources of funding here in Luxembourg ranging from what are essentially non-competitive grants that companies can apply for and likely to secure with appropriate documentation, to larger competitive funding opportunities."
